The Altshock-2 trial showed that routine early IABP plus standard care, vs. standard care only, did not significantly improve 60-day survival or successful bridging to HRT in patients with HF-CS.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...